{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(2)"],"submitter":["Kimura K"],"pubmed_abstract":["<h4>Objective</h4>To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of α4-integrin (CD49d).<h4>Methods</h4>Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8 healthy controls were included. The positive rate of CD49d was analyzed and compared among T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d+Th1, CD49d+Th17, and CD49d+Treg, respectively).<h4>Results</h4>Natalizumab treatment increased CD49d ratios, CD49d+Th1/CD49d+Treg, and CD49d+Th17/CD49d+Treg. This indicates larger reduction of the CD49d+ population in Treg cells than in Th1 or Th17 cells. The CD49d ratios of 2 patients who experienced exac"],"journal":["Neurology(R) neuroimmunology & neuroinflammation"],"pagination":["e210"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4784802"],"repository":["biostudies-literature"],"pubmed_title":["Disrupted balance of T cells under natalizumab treatment in multiple sclerosis."],"pmcid":["PMC4784802"],"pubmed_authors":["Nakamura M","Takahashi R","Murata M","Lin Y","Kimura K","Okamoto T","Araki M","Yamamura T","Sato W"],"additional_accession":[]},"is_claimable":false,"name":"Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.","description":"<h4>Objective</h4>To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of α4-integrin (CD49d).<h4>Methods</h4>Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8 healthy controls were included. The positive rate of CD49d was analyzed and compared among T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d+Th1, CD49d+Th17, and CD49d+Treg, respectively).<h4>Results</h4>Natalizumab treatment increased CD49d ratios, CD49d+Th1/CD49d+Treg, and CD49d+Th17/CD49d+Treg. This indicates larger reduction of the CD49d+ population in Treg cells than in Th1 or Th17 cells. The CD49d ratios of 2 patients who experienced exac","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Apr","modification":"2025-04-25T18:59:20.642Z","creation":"2019-03-27T02:10:45Z"},"accession":"S-EPMC4784802","cross_references":{"pubmed":["27006971"],"doi":["10.1212/NXI.0000000000000210"]}}